ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR®, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced financial results for the quarter ended Ju…
Author: Business Wire
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the ach…
Warby Parker Announces Second Quarter 2024 Results
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (“Warby Parker” or the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the second quarter ended June 30, 2024. “We’re proud of t…
National Vision Holdings, Inc. Announces Repurchase of $218 Million of Convertible Notes and Borrowing of $115 Million in Incremental Term Loans
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision”) today announced that it has reached agreement to repurchase approximately $218 million aggregate principal amount of its 2.50% Convertible Senior Notes due 2…
Johnjoe Farragher Named President & CEO of Hadley, World Leader Serving Older Adults Adjusting to Vision Loss
WINNETKA, Ill.–(BUSINESS WIRE)–The Board of Trustees of Hadley is pleased to announce the appointment of Johnjoe Farragher as next President and CEO of Hadley. He succeeds current President Julie Tye upon her retirement in September of this year. “In…
LumiThera anuncia el primer código CPT para informar sobre la terapia de fotobiomodulación en enfermedades de la retina primer paso hacia el reembolso
SEATTLE–(BUSINESS WIRE)–LumiThera, Inc, una compañía de dispositivos médicos que comercializa un tratamiento de fotobiomodulación (PBM) para el daño y la enfermedad ocular, ha anunciado hoy un nuevo código CPT de categoría III que entrará en vigor el…
LumiThera gibt ersten CPT Code für die Berichterstattung der Photobiomodulationstherapie bei Netzhauterkrankung bekannt – Erster Schritt zur Rückerstattung
SEATTLE–(BUSINESS WIRE)–LumiThera, Inc., ein Unternehmen für Medizingeräte für Photobiomodulation (PBM)-Behandlung bei Augenschäden und -erkrankungen, hat heute einen neuen Category III CPT Code mit Wirkung 1. Januar 2025 bekannt gegeben. Der AMA’s C…
LumiThera annonce le premier code CPT pour désigner le traitement par photobiomodulation des maladies de la rétine – un premier pas vers le remboursement.
SEATTLE–(BUSINESS WIRE)–LumiThera, Inc, une société de dispositifs médicaux commercialisant un traitement de photobiomodulation (PBM) pour les lésions et maladies oculaires, a annoncé aujourd’hui un nouveau code CPT de catégorie III qui entrera en vi…
LumiThera kondigt eerste CPT-code aan om fotobiomodulatietherapie bij netvliesaandoeningen te rapporteren – eerste stap richting vergoeding
SEATTLE–(BUSINESS WIRE)–LumiThera, Inc., een medisch hulpmiddelenbedrijf dat een fotobiomodulatiebehandeling (PBM) voor oogschade en -aandoeningen commercialiseert, heeft vandaag een nieuwe CPT-code van Categorie III aangekondigd die ingaat op 1 janu…
STAAR Surgical Reports Second Quarter 2024 Results
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial re…
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, August 8, 2024, at 9:00 a.m. (ET) to provide top-line results from the Phase 3 dry eye diseas…
Harrow Announces Second Quarter 2024 Financial Results
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the second quarter and six months ended June 30, 2024. The Company also posted its second quarter Letter …
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announce…
LENSAR Announces Certification for the ALLY® Adaptive Cataract Treatment System in the European Union
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced that the ALLY Adaptive Cataract Treatment S…
LumiThera Announces First CPT Code to Report Photobiomodulation Therapy in Retinal Disease – First Step Toward Reimbursement
SEATTLE–(BUSINESS WIRE)– #DryAMD–LumiThera, Inc., a medical device company commercializing a photobiomodulation (PBM) treatment for ocular damage and disease, today announced a new Category III CPT code effective January 1, 2025. The AMA’s CPT Edito…
National Vision Holdings, Inc. Reports Second Quarter 2024 Financial Results
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today reported its financial results for the second quarter ended June 29, 2024. “Comparable store sales growth in the second quarter improv…
National Vision Announces the Appointment of Alex Wilkes as President
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) today announced the appointment of Alex Wilkes as National Vision’s President, reporting to Reade Fahs, Chief Executive Officer of National Vision, effective August 19, 2024. Th…
Baxter Reports Second-Quarter 2024 Results
DEERFIELD, Ill.–(BUSINESS WIRE)–Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2024. “Baxter’s strategic transformation continues to gain momentum and drive performance benefiting our b…
Eyedaptic Unveils EYE6 with Ivy, A New AI Powered Visual Assistant for Individuals with Age-Related Macular Degeneration and Other Retinal Disorders
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Eyedaptic, a leader in vision-enhancement solutions, today unveiled its latest breakthrough, the EYE6 with Ivy, the only wearable vision aid that both enhances vision and provides an artificial intelligence (AI) p…
New Study Demonstrates Breakthrough with Retinal Progenitor Cell Therapy in a Preclinical Model of Photoreceptor Degeneration
IRVINE, Calif.–(BUSINESS WIRE)–Researchers from the Gavin Herbert Eye Institute and Sue & Bill Gross Stem Cell Research Center at the University of California, Irvine, in collaboration with the Neuroscience Research Institute at the University of…